Archifar Dosage/Direction for Use

Adults: The dosage and duration of therapy shall be established depending on type and severity of infection and the condition of the patient. The recommended daily dosage is as follows: 500 mg IV every 8 hrs in the treatment of pneumonia, UTI, gynaecological infections eg, endometritis, skin and skin structure infections.
Nosocomial Pneumonias, Peritonitis, Presumed Infections in Neutropenic Patients, Septicaemia: 1 g IV every 8 hrs.
Meningitis: Recommended Dose: 2 g every 8 hrs.
Infections Known or Suspected to be Caused by Pseudomonas aeruginosa: 1 g 3 times daily (or every 8 hrs) or higher is recommended.
There is limited safety data available to support a dose of >2 g 3 times daily (or every 8 hrs).
Children: Infections Known or Suspected to be Caused by Pseudomonas aeruginosa: Recommended Dose: Dose of up to 40 mg/kg 3 times daily (or every 8 hrs).
Regular sensitivity testing is recommended when treating Pseudomonas aeruginosa infection.
Children >3 months and up to 12 years: Recommended Dose: 10-20 mg/kg every 8 hrs depending on type and severity of infection, susceptibility of the pathogen and the condition of the patient.
Children >50 kg: Adult dosage should be used.
Meningitis: Recommended Dose: 40 mg/kg every 8 hrs.
There is no experience in children with renal impairment.
Elderly: No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values >50 mL/min.
Impaired Renal Function: Dosage should be reduced in patients with creatinine clearance (CrCl) <51 mL/min, as scheduled as follows: CrCl 26-50 mL/min: 1-unit dose every 12 hrs, CrCl 10-25 mL/min: ½-unit dose every 12 hrs and CrCl <10 mL/min: ½-unit dose every 24 hrs (based on unit doses of 500 mg).
Meropenem is cleared by haemodialysis and hemofiltration; if continued treatment with Archifar is necessary, it is recommended that the unit dose (based on the type and severity of infection) is administered at the completion of the haemodialysis procedure to restore therapeutically effective plasma concentrations.
There is no experience with the use of meropenem in patients under peritoneal dialysis.
Hepatic Insufficiency: No dosage adjustment is necessary in patients with hepatic insufficiency (see Precautions).
Administration: Archifar can be given as an IV bolus injection over approximately 5 min or by IV infusion over approximately 15-30 min using the specific available presentations.
There is limited safety data available to support the administration of a 40 mg/kg bolus dose.
There is limited safety data available to support the administration of a 2 g bolus dose.
Archifar to be used for bolus IV injection should be constituted with sterile water for injection (5 mL/250 mg meropenem). This provides an approximate concentration of 50 mg/mL.
Archifar for IV infusion may be constituted with compatible infusion fluids (see Interactions and Cautions for Usage).